Hope S. Rugo, MD, FASCO, discusses the role of abemaciclib plus elacestrant for ER+/HER2– MBC from data presented at SABCS 2024.

Panelists discuss how the final efficacy and safety analysis from the COMMANDS trial (Della Porta et al, Lancet 2024) highlights the role of luspatercept in first-line treatment for lower-risk ...

A panelist discusses how the phase 2 ELECTRA trial studies elacestrant in combination with ribociclib as first-line therapy for ER+/HER2– advanced breast cancer in postmenopausal women.